Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
Authors:
- Odile LaunayOLOdile Launay
- Xavier DuvalXDXavier Duval
- Serge FitoussiSFSerge Fitoussi
- Wolfgang JilgWJWolfgang Jilg
- Angkool KerdpanichAKAngkool Kerdpanich
- May MontellanoMMMay Montellano
- Tino F SchwarzTSTino F Schwarz
- Veerachai WatanveeradeVWVeerachai Watanveerade
- Jürgen J WenzelJWJürgen J Wenzel
- Gerard ZalcmanGZGerard Zalcman
- Vinod BambureVBVinod Bambure
- Ping LiPLPing Li
Open Access
- 16 September 2013
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 435
Abstract
Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/California/7/2009 (H1N1)v-like-AS03 vaccines manufactured in Dresden (D-Pan), and Quebec (Q-Pan).Keywords
This publication has 20 references indexed in Scilit:
- Atypical forms of Guillain-Barré syndrome and H1N1-influenza vaccinationVaccine, 2012
- Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 AdjuvantThe Journal of Infectious Diseases, 2012
- Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescentsVaccine, 2011
- Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunityVaccine, 2011
- Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trialThe Lancet Infectious Diseases, 2011
- An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workersVaccine, 2010
- AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of AgeClinical Infectious Diseases, 2010
- Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in AdultsThe Journal of Infectious Diseases, 2010
- Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trialVaccine, 2010
- Antibody induction by influenza vaccines in the elderly: a review of the literatureVaccine, 1989